Your AI-Trained Oncology Knowledge Connection!


Video

Dr. Yu on the Drawbacks of Radiation Therapy in Prostate Cancer

Author(s):

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses drawbacks of radiation therapy in prostate cancer.

Radiation therapy has become more advanced over the last few years, as researchers are better at tracking the tumor and delivering high doses of therapy while sparing normal tissue. With that being said, there are still challenges with this modality, Yu says. Side effects are still seen in patients, largely depending on the site of radiation.

For example, if radiation is delivered near the spinal cord, neurologic deficits can occur. Radiation near the bowels can cause gastrointestinal toxicities like severe diarrhea. The prostate sits in front of the rectum with the urethra and the bladder in close proximity, so prostate cancer is particularly challenging. There are multiple important organs nearby that radiation oncologists need to spare.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Yufei Liu, MD, PhD
Seema A. Bhat, MD, a hematologist at The Ohio State University Comprehensive Cancer Center—James; as well as an assistant professor in the Department of Internal Medicine in the Division of Hematology at The Ohio State University
Jacob Moyer, BS, of Mayo Clinic
Alfred L. Garfall, MD
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.